Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement.

19 Sep 2018

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand.

For further details see the attachment below.

STX_Exclusive Licence Agreement

Back to news